Ovarian cancer remains the most lethal gynaecologic tumour in the Western world. Stimulation of the immune system to consolidate response to chemotherapy can potentially be beneficial however so far none of the vaccination strategies have offered survival advantage. Thus identifying and targeting clinically relevant antigens for immunotherapy continues to be an important research strategy. We have evaluated Engrailed-2 (EN2) as a potential target for vaccine strategy. EN2 is a homeodomain-containing transcription factor with a multifunctional role in neural development. There is evidence that over-expression of EN2 protein maybe linked to tumour development.
|Journal||Journal of Clinical Oncology|
|Publication status||Published - 20 May 2011|
Bokaee, S., Michael, A., Riley, C., Denyer, M., Pandha, H. S., & Annels, N. E. (2011). EN2: A candidate antigen for the development of targeted therapies in ovarian cancer. Journal of Clinical Oncology, 29(15_suppl). https://doi.org/10.1200/jco.2011.29.15_suppl.e15528